Physician‐directed patient self‐management in heart failure using left atrial pressure: Interim insights from the VECTOR‐HF I and IIa studies

• Published in: European journal of heart failure Vol. 26; no. 8; pp. 1814 - 1823
• Main Authors: Meerkin, David, Perl, Leor, Hasin, Tal, Petriashvili, Shalva, Kurashvili, Levan, Metreveli, Mikheil, Ince, Hüseyin, Feickert, Sebastian, Habib, Manhal, Caspi, Oren, Jonas, Michael, Amat‐Santos, Ignacio J., Bayes‐Genis, Antoni, Codina, Pau, Koren, Oran, Frydman, Shir, Pachino, Rachel M., Anker, Stefan D., Abraham, William T.
• Format: Journal Article
• Language: English
• Published: Oxford, UK John Wiley & Sons, Ltd 01.08.2024
• Subjects: Heart failure; Left atrial pressure monitoring; Physician‐directed patient self‐management; Heart failure; Left atrial pressure monitoring; Physician‐directed patient self‐management
• ISSN: 1388-9842; 1879-0844
• DOI: 10.1002/ejhf.3338

Aims Haemodynamic monitoring using implantable pressure sensors reduces the risk of heart failure (HF) hospitalizations. Patient self‐management (PSM) of haemodynamics in HF has the potential to personalize treatment, increase adherence, and reduce the risk of worsening HF, while lowering clinicians' burden. Methods and results The VECTOR‐HF I and IIa studies are prospective, single‐arm, open‐label clinical trials assessing safety, usability and performance of left atrial pressure (LAP)‐guided HF management using PSM in New York Heart Association class II and III HF patients. Physician‐prescribed LAP thresholds trigger patient self‐adjustment of diuretics. Primary endpoints include the ability to perform LAP measurements and transmit data to the healthcare provider (HCP) interface and the patient guidance application, and safety outcomes. This is an interim analysis of 13 patients using the PSM approach. Over 12 months, no procedure‐ or device‐related major adverse cardiovascular or neurological events were observed, and there were no failures to obtain measurements from the sensor and transmit the data to the HCP interface and the patient guidance application. Patient adherence was 91.4%. Using PSM, annualized HF hospitalization rate significantly decreased compared to a similar period prior to PSM utilization (0 admissions vs. 0.69 admissions over 11.84 months, p = 0.004). At 6 months, 6‐min walk test distance and the Kansas City Cardiomyopathy Questionnaire overall summary score demonstrated significant improvement. Conclusions Interim findings suggest that PSM using a LAP monitoring system is feasible and safe. PSM is associated with high patient adherence, potentially improving HF patients' functional status, quality of life, and limiting HF hospitalizations. Interim insights from the VECTOR‐HF I and IIa studies. 6MWT, 6‐min walk test; f/u, follow‐up; HF, heart failure; KCCQ‐OS, Kansas City Cardiomyopathy Questionnaire overall summary; LAP, left atrial pressure; LVEF, left ventricular ejection fraction; M, month; MACNE, major adverse cardiovascular and neurological event; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; PSM, patient self‐management.